glp-1 agonists for type 2 diabetes receptor individualized treatment of mellitus Targeting GLP-1, GIP & GCG
Description
At month 3, engaged participants had a mean weight loss of 9% (95% CI 9% to 9.1%) compared with 5.9% (95% CI 5.9% to 6%) in nonengaged participants ( P 27.5 kg/m 2 , with the presence of obesity-related comorbidities
Comfort If your primary goal is significant weight reduction, dual-acting medications like Tirzepatide currently offer the highest clinical results
JMs PCP has requested a medication evaluation, inclusive of a review of his current diabetes care
Buzzetti, R., Maddaloni, E., Gaglia, J., Leslie, R
All GLP-1 drugs work by slowing gastric emptying to some degree, though individual responses vary
